Skip to main content

Adaptive Biotechnologies ClonoSEQ Expansion

Adaptive Biotechnologies has announced the expansion of its clonoSEQ process to include minimal residual disease analysis of cells harvested from patients with lymphoid cancers being prepared for autologous stem cell transplant. The expansion will allow physicians to prepare patients for autologous stem cell transplants by providing prognostic information that may potentially inform treatment decisions about maintenance post-transplant, Tom Willis, senior vice president and general manager of diagnostic products at Adaptive Biotechnologies, said in a statement. Physicians wishing to submit autograft samples should fill out the clonoSEQ MRD Test Requisition Form and submit samples using a clonoSEQ Specimen Kit to Adaptive's CLIA-certified, CAP-accredited laboratory in South San Francisco. Results will be available within seven days of sample receipt.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.